Judge Denies Fee Award To Pfizer In Celebrex Case
Months after winning a challenge to its three U.S. patents covering painkiller Celebrex, Pfizer will not be able to reach into Israeli generics maker Teva Pharmaceuticals' pockets to pay for legal...To view the full article, register now.
Already a subscriber? Click here to view full article